Company intelligence / Profile preview

Zhuhai Qi Microorganism Technology

Zhuhai, Guangdong Sheng, Chinasciencedirect.com ↗

Ownership: Private
Development stage: Commercial

Overview

Zhuhai Qi Microorganism Technology is a private Chinese biotech company focused on developing small molecule and herbal medicines for ophthalmic diseases, particularly age-related macular degeneration and dry eye syndromes. The company has advanced programs up to Phase 3 clinical trials, with five clinical trials registered as of May 2025. No detailed clinical results are publicly available, but the pipeline includes both small molecules and herbal-based therapeutics targeting significant unmet needs in eye health.

Therapeutic areas: Ophthalmology
Modalities: Small moleculeHerbal medicine
Industry: Biotech

Drug pipeline

1 asset

QA108

Beyond the preview

Go deeper on Zhuhai Qi Microorganism Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhuhai Qi Microorganism Technology.

Explore the full profile